Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-2M Thigh Injection Sub-study
NCT05896761Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Oct 2021; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05896761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896761.